Houston, TX, United States

Baylor College of Medicine

www.bcm.edu/
Houston, TX, United States

Baylor College of Medicine , located in the Texas Medical Center in Houston, Texas, US, is a health science university. It includes a medical school, Baylor College of Medicine; the Graduate School of Biomedical science; the School of Allied Health science; and the National School of Tropical Medicine. The school, located in the middle of the world's largest medical center, is part owner of Baylor St. Luke's Medical Center, part of the CHI St. Luke's Health system, and has hospital affiliations with: Harris Health System, Texas Children's Hospital, The University of Texas MD Anderson Cancer Center, Memorial Hermann - The Institute for Rehabilitation and Research, Menninger Clinic, the Michael E. DeBakey Veterans Affairs Medical Center and Children's Hospital of San Antonio.The medical school has been consistently considered in the top-tier of programs in the country, and is particularly noted for having the lowest tuition among all private medical schools in the US. Its Graduate School of Biomedical science is among the top 30 graduate schools in the United States. Within the School of Allied Health science, the nurse anesthesia ranks 5th and the physician assistant program ranks 6th. A program in Orthotics and Prosthetics began in 2013, with 18 students in the first class. The National School of Tropical Medicine is the only school in the nation dedicated exclusively to patient care, research, education and policy related to neglected tropical diseases.On June 21, 2010, Dr. Paul Klotman was named as the new President and CEO of the Baylor College of Medicine. In January 2014, the College and CHI St. Luke's became joint owners of Baylor St. Luke's Medical Center. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Baylor College of Medicine | Date: 2017-08-02

Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs.


Patent
Baylor College of Medicine | Date: 2017-03-22

The present invention relates to an intraosseous nerve ablation system comprising: a boring device adapted to form a passageway in bone, thereby providing access to an intraosseous nerve within the bone; an intraosseous nerve ablation device adapted to ablate the intraosseous nerve within the bone, wherein the intraosseous nerve ablation device comprises a shaft having a first end and a second end and a length defined therebetween, wherein the first end of the shaft comprises a tip formed of an electrically conductive material, wherein the tip of the shaft is blunt; a sleeve adapted to receive the intraosseous nerve ablation device and to facilitate alignment of the nerve ablation device with the passageway; and an electric power source operatively associated with the intraosseous nerve ablation device such that electrical current from the electric power source is transmitted to the first end of the intraosseous nerve ablation device, wherein the electrical current provided by the electric power source is sufficient to ablate the intraosseous nerve.


Patent
Baylor College of Medicine | Date: 2017-01-05

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.


Patent
Baylor College of Medicine and Rice University | Date: 2017-03-15

One aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position. Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.


Patent
Monash University, La Trobe University, Peptides International Inc. and Baylor College of Medicine | Date: 2017-06-21

Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X-4 is D, E or other negatively-charged amino acid or derivative thereof, X-3 is E, I, L, S, V, W or a tryptophan derivative, X-2 is any amino acid, X-1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.


Patent
Baylor College of Medicine | Date: 2017-06-21

The present disclosure relates to methods of treating AML associated with DNMT3A mutations by administering one or more DOTIL inhibitors or related pharmaceutical compositions to subjects in need thereof.


Patent
Baylor College of Medicine and Rice University | Date: 2017-03-07

A hearing device may provide hearing-to-touch sensory substitution as a therapeutic approach to deafness. Through use of signal processing on received signals, the hearing device may provide better accuracy with the hearing-to-touch sensory substitution by extending beyond the simple filtering of an incoming audio stream as found in previous tactile hearing aids. The signal processing may include low bitrate audio compression algorithms, such as linear predictive coding, mathematical transforms, such as Fourier transforms, and/or wavelet algorithms. The processed signals may activate tactile interface devices that provide touch sensation to a user. For example, the tactile interface devices may be vibrating devices attached to a vest, which is worn by the user. The vest may also provide other types of information to the user.


Ma W.J.,Baylor College of Medicine
Trends in Cognitive Sciences | Year: 2012

Probability has played a central role in models of perception for more than a century, but a look at probabilistic concepts in the literature raises many questions. Is being Bayesian the same as being optimal? Are recent Bayesian models fundamentally different from classic signal detection theory models? Do findings of near-optimal inference provide evidence that neurons compute with probability distributions? This review aims to disentangle these concepts and to classify empirical evidence accordingly. © 2012 Elsevier Ltd.


Noebels J.,Baylor College of Medicine
Nature Neuroscience | Year: 2015

Epilepsy genes deliver critical insights into the molecular control of brain synchronization and are revolutionizing our understanding and treatment of the disease. The epilepsy-associated genome is rapidly expanding, and two powerful complementary approaches, isolation of de novo exome variants in patients and targeted mutagenesis in model systems, account for the steep increase. In sheer number, the tally of genes linked to seizures will likely match that of cancer and exceed it in biological diversity. The proteins act within most intracellular compartments and span the molecular determinants of firing and wiring in the developing brain. Every facet of neurotransmission, from dendritic spine to exocytotic machinery, is in play, and defects of synaptic inhibition are over-represented. The contributions of somatic mutations and noncoding microRNAs are also being explored. The functional spectrum of established epilepsy genes and the arrival of rapid, precise technologies for genome editing now provide a robust scaffold to prioritize hypothesis-driven discovery and further populate this genetic proto-map. Although each gene identified offers translational potential to stratify patient care, the complexity of individual variation and covert actions of genetic modifiers may confound single-gene solutions for the clinical disorder. In vivo genetic deconstruction of epileptic networks, ex vivo validation of variant profiles in patient-derived induced pluripotent stem cells, in silico variant modeling and modifier gene discovery, now in their earliest stages, will help clarify individual patterns. Because seizures stand at the crossroads of all neuronal synchronization disorders in the developing and aging brain, the neurobiological analysis of epilepsy-associated genes provides an extraordinary gateway to new insights into higher cortical function. © 2015 Nature America, Inc. All rights reserved.


Kurtova A.V.,Baylor College of Medicine
Nature | Year: 2015

Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some patients tumours become progressively unresponsive after multiple treatment cycles. Previous studies have demonstrated that cancer stem cells (CSCs) are selectively enriched after chemotherapy through enhanced survival. Here we reveal a new mechanism by which bladder CSCs actively contribute to therapeutic resistance via an unexpected proliferative response to repopulate residual tumours between chemotherapy cycles, using human bladder cancer xenografts. Further analyses demonstrate the recruitment of a quiescent label-retaining pool of CSCs into cell division in response to chemotherapy-induced damages, similar to mobilization of normal stem cells during wound repair. While chemotherapy effectively induces apoptosis, associated prostaglandin E2 (PGE2) release paradoxically promotes neighbouring CSC repopulation. This repopulation can be abrogated by a PGE2-neutralizing antibody and celecoxib drug-mediated blockade of PGE2 signalling. In vivo administration of the cyclooxygenase-2 (COX2) inhibitor celecoxib effectively abolishes a PGE2- and COX2-mediated wound response gene signature, and attenuates progressive manifestation of chemoresistance in xenograft tumours, including primary xenografts derived from a patient who was resistant to chemotherapy. Collectively, these findings uncover a new underlying mechanism that models the progressive development of clinical chemoresistance, and implicate an adjunctive therapy to enhance chemotherapeutic response of bladder urothelial carcinomas by abrogating early tumour repopulation.

Loading Baylor College of Medicine collaborators
Loading Baylor College of Medicine collaborators